All Companies
Ticker QURE
SEC data is missing this company's latest quarter
You reached the page — here's exactly what QURE is, and why it's out of scope for now.
What this ticker is
QURE
uniQure N.V.
NASDAQ
Healthcare
Biotechnology
Netherlands
Mkt cap $3.1B
uniQure N.V. is a biopharmaceutical company focused on gene therapy for patients with severe genetic and other serious diseases. Its current portfolio includes HEMGENIX for hemophilia B and a pipeline of investigational therapies aimed at disorders such as Huntington’s disease, epilepsy, ALS, and Fabry disease. The company uses an adeno-associated virus (AA…
Why we can't analyze it yet
SEC data is missing this company's latest quarter: the SEC's companyfacts (refetched) ends at 2026-03-31 while its index lists a statement period 2026-06-30 — the SEC's aggregation omitted the filing; not recoverable from any archive we read Found by the Foundation Sweep four-quarter pass 2026-09-11; held under the four-quarter coverage policy (2026-09-11) and released automatically once the pass resolves it.
Delvantic analyzes regular securities of single operating companies — one business with revenue, earnings and cash flows our valuation methods can assess bottom-up.
Reason code:
sec_omission